Drugs / TSL-1502
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05420779 | Jun 2022 → Dec 2024 | breast carcinoma | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSL-1502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05420779 ↗ |
| Route | Oral | “orally administered QD” NCT05420779 ↗ |